Generic Hypertension Drug Gains FDA Approval


Generic version of olmesartan medoxomil and hydrochlorothiazide tablets treat hypertension to lower blood pressure.

The FDA has approved Aurobindo Pharma’s generic version of olmesartan medoxomil and hydrochlorothiazide tablets in 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg doses.

The reference listed drug, Daiichi Sankyo’s Benicar HCT tablets are indicated to treat hypertension to lower blood pressure.

The combined use of olmesartan medooxmil and hydrochlorothiazide was evaluated for safety in a clinical trial including 1243 hypertensive patients. Treatment with the combination drug was well tolerated, with an incidence of adverse events similar to that of a placebo. In the study, the most commonly reported adverse effects included nausea, hyperuricemia, dizziness, and upper respiratory infection, and occurred more often in the olmesartan medoxomil and hydrochlorothiazide combination than on the placebo.

The FDA previously granted the generic tentative approval in 2016 before its final approval.


Aurobindo receives FDA approval for olmesartan medoxomil and hydrochlorothiazide Tablets [press release]. East Windsor, N.J. Aurobindo Pharma Limited. Accessed May 1, 2017.

Related Videos
Image credit: Dr_Microbe |
Home Diabetes Treatment - Image credit: Dglimages |
Image credit: Azee/ |
Image credit: Elena |
Cropped view of senior man playing with puzzles on table- Image credit: LIGHTFIELD STUDIOS |
Breast cancer with lymphatics, medically 3D illustration | Image Credit: Axel Kock -
Woman with pink ribbon on color background. Breast cancer awareness concept | Image Credit: Pixel-Shot -
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store- Image credit: C Daniels/ |
View in microscopic of pathology cross section tissue ductal cell carcinoma or adenocarcinoma diagnosis by pathologist in laboratory | Image Credit: arcyto -
© 2023 MJH Life Sciences

All rights reserved.